We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.75 | 4.32% | 42.25 | 41.50 | 43.00 | 42.50 | 40.50 | 40.50 | 97,886 | 10:23:56 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 103.05 | 53.16M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/10/2017 15:17 | SDX,interview with PW at Proactive. Says | 11_percent | |
05/10/2017 15:17 | SDX,interview with PW at Proactive. Says | 11_percent | |
05/10/2017 14:54 | Old Mutual has doubled its holding in PRSM, janeann. apad | apad | |
05/10/2017 14:09 | HLMA breakout - at long last! apad | apad | |
05/10/2017 13:55 | red, Just checking you got my response to your private message? apad | apad | |
05/10/2017 13:21 | hxxps://www.sharepro hxxps://www.allagent Ouch! | al101uk | |
05/10/2017 12:39 | Oh come on cloudtag rns's took some beating lol | panic investor | |
05/10/2017 12:30 | FARN - happy with the placing, the key take away is that in every placing, the price has been higher and insiders/directors have partake in BOO - Old Mutual increase by a smidgeon, key takeaway is that they did not reduce their stake on the results update/Kane stake reduction Everything else is just noise. If it falls back to 180 (as all the technical traders seem keen to point out), will look to increase stake substantially | sherylchan | |
05/10/2017 12:17 | It's the most amazing RNS I've read for some time. It would not have attracted me as an investment but I still can't believe the change since last trading statement. All very odd. Bad luck to those caught out. | hydrus | |
05/10/2017 12:10 | Questor tipped it on September 5 I think - just goes to show ! | panic investor | |
05/10/2017 11:55 | That ACRL statement is an absolute shocker. One month ago everything was fine according to the company and now suddenly the world has ended. When the suspension ends I expect it's a -50% plus drop. It's not the kind of company I would invest in as margins too tight. However, one could understand why others might based on previous metrics and recent statements. I do not believe it would have been possible to predict today's news.A good reminder that investors should never be complacent or too confident on any position. Over-confidence is a killer and it's sometimes displayed on this board in my view (including by me previously!) | hydrus | |
05/10/2017 10:33 | As I understand the story they will be rolling out Traumakine themselves in different countries, dacian. A small pharmaceutical company with a unique, flagship product doesn't come along that often. Also one that is not run by a bunch of professional managers who will sell out at the drop of a hat. I don't know anything about their other products on trial. apad | apad | |
05/10/2017 09:56 | "the AIM-listed leading independent tissue converter" Sometimes a few words are all that is needed to put one off buying a share. I suppose it could've been worse - a nano-tissue converter perhaps :-) apad | apad | |
05/10/2017 09:38 | Not me Red - looks like a shocker though. Seen it tipped all over the place. | hydrus | |
05/10/2017 09:35 | Note to me: "It is a constant worry when the crash will happen again. Next time there may be no recovery. One thing's for sure - us plebs won't have any advanced warning. Rick" | apad | |
05/10/2017 09:34 | Hope no one holds ACRL, I recall it being mentioned here by hydrus possibly.GAW, what a monster share, it's still incredibly cheap on per of 13 for such a growth story.GLEN, will have almost monopoly on the precious metal zinc after the announcement a few days ago. | modform | |
05/10/2017 09:29 | I think INTEREST is a foregone conclusion, dacian. As I've opined before, I think Phase III's job is to better define the boundaries of Phase II results. Anyway, they are Finns - who are renowned for not putting the sledge before the reindeer. apad | apad | |
05/10/2017 09:23 | ZOO keeps powering on. I took profits at 150% and 250% but still have 85% of my original holding. Hopefully there is a long way to go with both existing services which are growing very rapidly and their new dubbing service, which seems to have good initial traction. I can't see better opportunities still in sub £30m Mcap stocks. | hydrus | |
05/10/2017 09:23 | APAD Thanks. Bit of work to do. Your opinion is substantially the same as mine. Few days of concentrated effort required, but do I have the will? Not sure. red | redartbmud | |
05/10/2017 09:15 | SDX back to my buy price - as I sold some SOU near the top to buy them I suppose that isn't all that bad. FARN still over the placing price - can't see people selling that bad baby! BOO is beyond my understanding. Kane's sale was mopped up at 230p - so doesn't that make sub 200p a steal? apad | apad | |
05/10/2017 09:00 | Replied to private message, red. apad | apad | |
05/10/2017 07:58 | Nanoco A measure of the 'success' so far - the begging bowl. Following the announcement made at 4.40 p.m. on 4 October 2017 in respect of the proposed £8.6 million fundraising (the "Fundraising Announcement"), the Board of Nanoco Group PLC ("Nanoco" or the "Company" or, together with its subsidiaries, the "Group") is pleased to announce that the Company has successfully placed 22,546,405 new Ordinary Shares at a price of 18 pence per share to institutional investors pursuant to the Placing. As such, Lombard Odier's subscription has been scaled back to 23,827,911 new Ordinary Shares. The final Director and Senior Management Subscription was for 1,281,505 new Ordinary Shares, as stated in the Fundraising Announcement. What a cr*p investment!! red | redartbmud |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions